Cancer treatment and research最新文献_第6页

Redefining Cultural Competency: Practicing Cultural Humility. 重新定义文化能力：践行文化谦逊。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-29923-0_1

Bernie White, Mariela Gallo, Alexsandra Morales

引用次数: 0

The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer. SWI/SNF 复合物：癌症中经常发生突变的染色质重塑复合物

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_7

Vinh The Nguyen, Mathewos Tessema, Bernard Ellis Weissman

{"title":"The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.","authors":"Vinh The Nguyen, Mathewos Tessema, Bernard Ellis Weissman","doi":"10.1007/978-3-031-45654-1_7","DOIUrl":"10.1007/978-3-031-45654-1_7","url":null,"abstract":"The switch/sucrose non-fermenting (SWI/SNF) chromatin remodeling complex is a global regulator of gene expression known to maintain nucleosome-depleted regions at active enhancers and promoters. The mammalian SWI/SNF protein subunits are encoded by 29 genes and 11-15 subunits including an ATPase domain of either SMARCA4 (BRG1) or SMARCA2 (BRM) are assembled into a complex. Based on the distinct subunits, SWI/SNF are grouped into 3 major types (subfamilies): the canonical BRG1/BRM-associated factor (BAF/cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (GBAF/ncBAF). Pan-cancer genome sequencing studies have shown that nearly 25% of all cancers bear mutations in subunits of the SWI/SNF complex, many of which are loss of function (LOF) mutations, suggesting a tumor suppressor role. Inactivation of SWI/SNF complex subunits causes widespread epigenetic dysfunction, including increased dependence on antagonistic components such as polycomb repressor complexes (PRC1/2) and altered enhancer regulation, likely promoting an oncogenic state leading to cancer. Despite the prevalence of mutations, most SWI/SNF-mutant cancers lack targeted therapeutic strategies. Defining the dependencies created by LOF mutations in SWI/SNF subunits will identify better targets for these cancers.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"190 ","pages":"211-244"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer. 治疗乳腺癌患者的快速模拟饮食和其他创新营养干预措施。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-33602-7_8

Federica Giugliano, Laura Boldrini, Jacopo Uliano, Edoardo Crimini, Ida Minchella, Giuseppe Curigliano

引用次数: 0

Hormonal Therapies in Cancers. 癌症的激素治疗。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-27156-4_6

Muhammad Rizwan Tariq, Shinawar Waseem Ali, Sehar Anam Khan, Roshan Yamen, Sara Iqbal, Waseem Safdar, Muhammad Naveed Sheas

引用次数: 0

Targeted Therapy and Personalized Medicine. 靶向治疗和个性化医疗。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-27156-4_10

Rida Fatima Saeed, Uzma Azeem Awan, Sidra Saeed, Sara Mumtaz, Nosheen Akhtar, Shaista Aslam

{"title":"Targeted Therapy and Personalized Medicine.","authors":"Rida Fatima Saeed, Uzma Azeem Awan, Sidra Saeed, Sara Mumtaz, Nosheen Akhtar, Shaista Aslam","doi":"10.1007/978-3-031-27156-4_10","DOIUrl":"https://doi.org/10.1007/978-3-031-27156-4_10","url":null,"abstract":"Targeted therapy and personalized medicine are novel emerging disciplines of cancer research intended for treatment and prevention. One of the most significant advancements in modern oncology is the shift from an organ-centric strategy to a personalized strategy guided by deep molecular analysis. This shift in view, which focuses on the tumour's precise molecular changes, has paved the way for individualized treatment. Researchers and clinicians are using targeted therapies to select the best treatment available based on the molecular characterization of malignant cancer. In the treatment of a cancer, personalized medicine entails the use of genetic, immunological, and proteomic profiling to provide therapeutic alternatives as well as prognostic information about cancer. In this book, targeted therapies and personalized medicine have been covered for specific malignancies, including latest FDA-approved targeted therapies and it also sheds light on effective anti-cancer regimens and drug resistance. This will help to enhance our ability to conduct individualized health planning, make early diagnoses, and choose optimal medications for each cancer patient with predictable side effects and outcomes in a quickly evolving era. Various applications and tools' capacity have been improved for early diagnosis of cancer and the growing number of clinical trials that choose specific molecular targets reflects this predicament. Nevertheless, there are several limitations that must need to be addressed. Hence, in this chapter, we will discuss recent advancements, challenges, and opportunities in personalized medicine for various cancers, with a specific emphasis on target therapies in diagnostics and therapeutics.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"185 ","pages":"177-205"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Introduction and Overview of Cancer Therapeutics. 癌症治疗学的介绍和概述。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-27156-4_1

Asma Saleem Qazi

引用次数: 0

Making Decisions When No Further Diagnostic Testing is Available. 当没有进一步的诊断测试可用时做出决定。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-37993-2_2

Benjamin Djulbegovic, Iztok Hozo

引用次数: 0

Medical Decision-Making and Artificial Intelligence. 医疗决策与人工智能。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-37993-2_9

Benjamin Djulbegovic, Iztok Hozo

引用次数: 0

Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives. 乳腺癌新辅助治疗的评估和反应：当前实践、反应监测、未来方法和前景。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-33602-7_5

Vincenzo Sabatino, Alma Pignata, Marvi Valentini, Carmen Fantò, Irene Leonardi, Michela Campora

{"title":"Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives.","authors":"Vincenzo Sabatino, Alma Pignata, Marvi Valentini, Carmen Fantò, Irene Leonardi, Michela Campora","doi":"10.1007/978-3-031-33602-7_5","DOIUrl":"10.1007/978-3-031-33602-7_5","url":null,"abstract":"Neoadjuvant treatments (NAT) for breast cancer (BC) consist in the administration of chemotherapy-more rarely endocrine therapy-before surgery. Firstly, it was introduced 50 years ago to downsize locally advanced (inoperable) BCs. NAT are now widespread and so effective to be used also at the early stage of the disease. NAT are heterogeneous in terms of therapeutic patterns, class of used drugs, dosage, and duration. The poly-chemotherapy regimen and administration schedule are established by a multi-disciplinary team, according to the stage of disease, the tumor subtype and the age, the physical status, and the drug sensitivity of BC patients. Consequently, an accurate monitoring of treatment response can provide significant clinical advantages, such as the treatment de-escalation in case of early recognition of complete response or, on the contrary, the switch to an alternative treatment path in case of early detection of resistance to the ongoing therapy. Future is going toward increasingly personalized therapies and the prediction of individual response to treatment is the key to practice customized care pathways, preserving oncological safety and effectiveness. To gain such goal, the development of an accurate monitoring system, reproducible and reliable alone or as part of more complex diagnostic algorithms, will be promising.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"188 ","pages":"105-147"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139085983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go? 晚期乳腺癌的新一代测序：何去何从？

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-33602-7_13

Dario Trapani, Edoardo Crimini, José Sandoval, Giuseppe Curigliano

{"title":"Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?","authors":"Dario Trapani, Edoardo Crimini, José Sandoval, Giuseppe Curigliano","doi":"10.1007/978-3-031-33602-7_13","DOIUrl":"10.1007/978-3-031-33602-7_13","url":null,"abstract":"The rapid implementation of precision medicine tools in diagnosing and treating breast cancer (BC) has widened the potential therapeutic options for patients. The applications of gene sequencing, including next-generation gene sequencing (NGS), have led to numerous questions on how to validate, implement, interpret, prioritize and operationalize precision medicine tools to deliver meaningful and impactful interventions. Limited benefit has been portended with earlier experiences of NGS-driven treatment, in BC. However, the development and use of frameworks of clinical actionability of genomic alterations, for example, detected with NGS, has resulted in better patient selection, and potentially higher therapeutic value. The European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) is a framework that includes five tiers of clinical actionability, with tier 1 reserved for approved drugs with demonstrated benefits for targetable genomic alterations. The re-analysis of clinical studies by grouping the genomic alterations and matched drugs with ESCAT, in high vs lower tiers has demonstrated a significant benefit portended by high tiers alterations, with the availability of efficacious treatments. As a result, frameworks for actionability, like ESCAT, should be fundamental in developing and implementing NGS-driven, and broadly, precision medicine research and treatments.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"188 ","pages":"343-351"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0